257 related articles for article (PubMed ID: 27896368)
1. Targeting of the WT1
Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
3. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
4. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
5. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
[TBL] [Abstract][Full Text] [Related]
6. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
[TBL] [Abstract][Full Text] [Related]
8. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P
Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
10. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
11. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
[TBL] [Abstract][Full Text] [Related]
12. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells.
Koido S; Tanaka Y; Tajiri H; Gong J
Vaccine; 2007 Mar; 25(14):2610-9. PubMed ID: 17239504
[TBL] [Abstract][Full Text] [Related]
13. Defining MHC class II T helper epitopes for WT1 tumor antigen.
Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
[TBL] [Abstract][Full Text] [Related]
14. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
[TBL] [Abstract][Full Text] [Related]
15. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
16. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpet-hemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia.
Kitawaki T; Kadowaki N; Kondo T; Ishikawa T; Ichinohe T; Teramukai S; Fukushima M; Kasai Y; Maekawa T; Uchiyama T
Am J Hematol; 2008 Apr; 83(4):315-7. PubMed ID: 18081032
[TBL] [Abstract][Full Text] [Related]
17. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
18. Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.
Willemen Y; Van den Bergh JM; Lion E; Anguille S; Roelandts VA; Van Acker HH; Heynderickx SD; Stein BM; Peeters M; Figdor CG; Van Tendeloo VF; de Vries IJ; Adema GJ; Berneman ZN; Smits EL
Cancer Immunol Immunother; 2015 Jul; 64(7):831-42. PubMed ID: 25863943
[TBL] [Abstract][Full Text] [Related]
19. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
[TBL] [Abstract][Full Text] [Related]
20. Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.
Romano E; Cotari JW; Barreira da Silva R; Betts BC; Chung DJ; Avogadri F; Fink MJ; St Angelo ET; Mehrara B; Heller G; Münz C; Altan-Bonnet G; Young JW
Blood; 2012 May; 119(22):5182-90. PubMed ID: 22510877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]